Modality
Gene Therapy
MOA
GLP-1ag
Target
Cl18.2
Pathway
DDR
PSPHCCWet AMD
Development Pipeline
Preclinical
~Apr 2019
→ ~Jul 2020
Phase 1
~Oct 2020
→ ~Jan 2022
Phase 2
~Apr 2022
→ ~Jul 2023
Phase 3
Oct 2023
→ Jul 2028
Phase 3Current
NCT08457926
2,269 pts·HCC
2023-10→2028-07·Active
2,269 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-07-112.3y awayPh3 Readout· HCC
Trial Timeline
Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P3
Active
Catalysts
Ph3 Readout
2028-07-11 · 2.3y away
HCC
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08457926 | Phase 3 | HCC | Active | 2269 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| ARG-1250 | Argenx | Phase 2 | C5 |